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ABSTRACT
Induction of PC12 pheochromocytoma cells neuronal
differentiation upon treatment with nerve growth factor
(NGF) is accompanied by a coupled stimulation of c-
fos and c-jun oncogene transcription. We found that
induction of c-fos and c-jun proto-oncogene mRNAs
levels following the endocrine differentiation of PC12
cells by sodium butyrate is uncoupled. While c-fos
mRNA level increased within minutes, the content of
c-jun mRNA was significantly elevated only 24 hours
after treatment. Continuous presence of sodium
butyrate for 72 hours resulted in stable high levels of
c-fos and c-jun mRNAs. Gene transcription of the other
members of the jun family, jun B and jun D, was not
significantly modified at any induction time. The early
accumulation of c-fos mRNA was accompanied by
increased levels of c-Fos protein. While the NGF-
induced c-Fos protein migrates with an apparent
homogeneous molecular weight of 62 kDa, the sodium
butyrate-stimulated Fos protein is of heterogeneous
lower molecular weight. The different gel mobility of
the Fos immunoreactive bands induced by sodium
butyrate and the sustained Fos mRNA levels after
induction suggested that the sodium butyrate-induced
c-Fos protein could be non-functional in the
autoregulation of the c-fos gene. Gel shift analysis
showed unimpaired capacity of the butyrate-induced
c-Fos protein to participate in the formation of
transcriptional complexes with the Jun/AP-1 protein.
However, transfection experiments indicate that the
sodium butyrate-induced c-Fos protein is not able to
negatively trans-regulate the c-fos promoter.
INTRODUCTION
Phenotypic conversion between cell derivatives from the caudal
part of the neural crest is a multidirectional phenomenon
conducted by a discrete number of factors. Among these,
glucocorticoids, nerve growth factor (NGF) and a 45-kDa
glycoprotein (cholinergic neuronal differentiation factor), direct
precursor cell differentiation to chromaffin cells, adrenergic and
cholinergic neurons, respectively (1, 2).
PC12 pheochromocytoma cells, a cell line phylogenetically
related to the sympathoadrenal precursor ofthe neural crest, offer
a similar plasticity. Indeed, PC12 cells exhibit a well
characterized neuronal phenotype upon treatment with NGF (3)
and, more recently, it has been shown that exposure of PC12
cells to sodium butyrate stops cell division and leads to a form
which resembles the chromaffin phenotype (4, 5).
Morphologically, sodium butyrate-differentiated PC12 cells show
a tendency to form clusters of pseudo-syncytial appearance
without neurite formation (4). Several tissue-specific changes are
observed in the pattern of gene expression following sodium
butyrate treatment including an increased expression of the pre-
proenkephalin gene (5), new expression of enolase
immunoreactivity (4), a reduced expression of tyrosine
hydroxylase and NGF receptor genes (J.R.N. and B.M., in
preparation). Long exposure ( 24 days) to glucocorticoids also
results in a chromaffin phenotype which shows a decrease in the
low affinity NGF receptor binding sites (6).
Expression of nuclear proto-oncogenes has been correlated with
the induction of proliferation or differentiation in different cell
systems (for review see ref. 7). Among these, c-fos is the most
extensively studied. It has been shown that the Fos protein acts
through the formation of specific complexes with other nuclear
proteins bearing a 'leucine zipper' domain close to a DNA-
binding basic motif (8-13). AP-1, a transcription factor identified
as the product of the proto-oncogene c-jun (14, 15), associates
with the c-Fos protein to bind and activate transcription from
promoter elements responsive to phorbol-esters (8-13).
Furthermore, the products of two more recently described genes
with sequence similarity to c-jun, jun B and jun D, may also
form nuclear complexes with c-Fos or Fos-related proteins and
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in that way might combinatorially modulate gene expression and
cell proliferation (16-18).
Previous studies have shown a transient coordinate induction
of c-fos, c-jun andjun B when PC12 cells are induced to divide
by epidermal growth factor or to differentiate along the neuronal
pathway by NGF (3, 19-24 ). Moreover, c-fos (19, 24-29)
and jun B (28) are induced in PC12 cells following membrane
depolarization, while c-jun does not respond to this stimulus (28).
To better understand the possible physiological meaning of the
changes in nuclear proto-oncogene expression in PC12
pheochromocytoma cells, we sought evidence for an involvement
offos andjun in the process of PC12 cells differentiation towards
the endocrine (chromaffin) phenotype after sodium butyrate
exposure. In this report, we show that the induction of the proto-
oncogenes fos andjun upon sodium butyrate treatment of PC 12
cells is uncoupled. In particular, c-fos mRNA level is elevated
up to 72 hrs after induction. We also show that autoregulation
by the Fos protein does not occur in sodium butyrate treated PC12
cells, and suggest that this is due to the fact that, upon sodium
butyrate treatment, the Fos protein undergoes some important
modifications.
MATERIALS AND METHODS
Cell culture
PC12 cells were grown directly on untreated plastic (Falcon) as
described (6). Drugs (Sigma) were added to exponentially
growing non-confluent cultures at concentrations and durations
specified in the figure legends.
Northern blot analysis
Total cellular RNA was isolated by CsCl centrifugation of
guanidium thiocyanate lysates. Size-fractionation of RNA was
achieved by electrophoresis on agarose-formaldehyde gels as
described (5). 32p labeled cDNA probes were prepared using the
random oligonucleotide priming method (Oligo-labeling kit,
Pharmacia) to specific activity equal to or higher than 7 x 108
cpm/,tg. Conditions for blot hybridization and washing have been
described elsewhere (5).
Isolation of nuclei and Western blot analysis
Cell nuclei from induced and uninduced cells were isolated and
lysates prepared as described (30). 10 jig of protein (Bradford
micromethod, BioRad) from each sample were applied per well
to a 10% NaDodSO4-polyacrylamide gel. After electroblotting
and blocking in 20% fetal calf serum and 5% defatted milk in
TBST buffer (50 mM Tris HCI pH8.0, 150 mM NaCl, 0.005%
Tween 20), the nitrocellulose membranes (High-bond,
Amersham) were incubated with an affinity purified c-Fos
antibody (a generous gift from Dr. Michael ladarola) for one
hour. Signal was developed using a goat anti-rabbit
immunoglobulin coupled to alkaline phosphatase (pico BlueTM
system, Stratagene) according to the manufacturer indications.
Gel retardation analysis
Five ,ug aliquots from each nuclear extract were used in each
binding assay. The assays were performed as described (8, 31),
using a 18 bp TRE oligodeoxynucleotide bearing the consensus
TGACTCA sequence (8). Inhibition of complex formation with
anti-Fos antibodies (against the M peptide, 32) and anti-Jun
antibodies (against the PEP-1 peptide, 14) was performed as
described (8, 9).
Transfection of cultured cells
Rat pheochromocytoma PC12 cells were plated in DMEM 10%
fetal calf serum, 5% horse serum, at 1 x 106 cells per 10 cm
tissue culture dish, 24 hr before DNA transfection. Cells were
transfected by the calcium phosphate coprecipitation technique
and CAT assays were performed as described (8). All
recombinants used in this study have already been described (8).
The BK28/A plasmid is a human c-fos expression vector with
an internal deletion in the (3' end carboxy terminus of the coding
region) of the cDNA generated by excising a BstEll fragment.
When less than 20 Ag of specific DNA was used, pGEM4 plasmid
DNA was added to give 20 itg of total transfected DNA.
Inductions by NGF and sodium butyrate were performed 24 -36
hrs after DNA transfection.
RESULTS
Uncoupling of fos and jun induction
To better understand the possible role of fos and jun
protooncogenes in the process of PC12 cell differentiation, we
studied their transcriptional induction upon treatment with sodium
butyrate. Addition of sodium butyrate (6 mM) to PC12 cell
cultures resulted in a rapid increase in c-fos mRNA accumulation.
The increase in c-fos mRNA was significant within dtirty minutes
after sodium butyrate addition, and peaked three hours later. Six
hours after sodium butyrate administration, the level of c-fos
mRNA was still 6-fold higher than the uninduced control levels,
and at 24 hours the induction was stabilized between 5 and 6
fold. In contrast, the levels of c-jun, jun B and jun D mRNA
were unchanged or slightly reduced during the first three hours
of treatment (Fig. 1). There is no detectable transcript of c-jun
between 0 and 6 hours after induction (data not shown, see fig.
iB). Between six and twenty four hours following sodium
butyrate treatment the level of c-jun mRNA increased 6 to 8-fold
over control values. No induction ofjun B orjun D was evident
even at later times. Three days after sodium butyrate the content
of c-jun mRNA had stabilized at a level 5-fold higher than that
in uninduced cells (fig. iB).
These results are quite distinct from the NGF induction
characteristics of these genes in PC12 cells (see fig. iB, refs
20-29). Effects of NGF administration were also measured at
late times for comparative purposes. A 1.5-fold increase was
observed for c-fos and c-jun mRNAs six hours after NGF
administration and by 24 hours no increase of c-fos mRNA
remained and a slight reduction in c-jun mRNA was observed
(fig. IB).
The effects of sodium butyrate onfos andjun expression were
linear over the concentration range 0.1 to 6 mM (not shown),
the same range which was previously described to efficiently stop
cell division (4). Since sodium butyrate is unstable in the culture
medium (4, 5), the highest concentration (6 mM) was used in
all other experiments. For the same reason, in treatments longer
than 24 hours, medium with sodium butyrate was replaced every
day.
The effects ofNGF and sodium butyrate on PC12 cell division
and differentiation are dependent on the continuous presence of
the drug in the culture medium and their removal reestablish
mitosis (3-5). When PC12 cells were exposed to sodium butyrate
for different time periods, after which the medium was removed
and the cultures maintained in control medium, the levels of c-
fos mRNA returned to basal values (results not shown).
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Figure 1. Induction of c-fos and members of the jun gene family upon sodium butyrate treatment of PC12 cells. a) Northern blot analysis of mRNA levels after
6 h and 24 h of sodium butyrate (B) or NGF (N) treatments (20 isg of total RNA were applied in each lane). Basal control levels are also indicated (C). Fos induction
is sustained between 6 and 24 hrs; mRNA levels of NGF-receptor gene transcription (NGF-R) are also shown for comparison. NGF-receptor gene transcription
decreases at 24 h treatment with sodium butyrate, but not with NGF (lanes 5-6, and B.M., in preparation). b) Time-course of c-fos and c-jun inductions upon
NGF (top panel) and sodium butyrate (bottom) treatments. The values blotted are obtained after scanning of Northern blot autoradiograms and, in the case of NGF
early induction times, also confirmed by published studies (23, 41).
Unusual modifications of Fos protein
Transcriptional autoregulation of both c-fos and c-jun expression
has been demonstrated (31, 33). Through binding to an AP-1
site in the c-jun promoter, Fos/Jun complexes trans-activate the
c-jun gene (33), while, in contrast, the.dyad symmetry element
(DSE) of the c-fos promoter mediates the trans-repression by Fos
of the c-fos gene (31). This negative feed-back mechanism
explains in part the transient nature of the c-fos mRNA or protein
accumulation in different experimental models (19-28, 34, 35),
and the phenomenon of superinduction of the c-fos gene after
co-administration of protein synthesis inhibitors (22, 23, 36, 37).
Furthermore, the reduction of c-Fos protein level may contribute
to the termination of the auto-activation of c-jun (AP-1) (33).
The possibility of a deficient process of translation of the c-fos
mRNA induced by sodium butyrate, or a non-completed post-
translational maturation of the c-Fos protein was investigated to
explain the longer permanence of elevated levels of c-fos and
c-jun mRNAs in PC12 cells after sodium butyrate administration.
Using Western blot analysis we observed an increase in c-Fos
immunoreactivity following the accumulation of c-fos mRNA (fig.
2). In keeping with previous reports (25, 27, 38), nuclear extracts
from normally growing cultures showed the presence of a group
of c-Fos immunoreactive bands in the 30-40 kDa area but very
low or undetectable levels of mature p62 c-Fos protein (p55fos
is modified by phosphorylation to a protein apparently of 62 kDa,
ref. 39 and data not shown). The exact nature of the
immunoreactivity in the 40 kDa area is unclear though some have
been identified as Fos-related proteins (Fos B and Fra-1, refs
38, 40) and as Jun/AP-1-associated polypeptides (8-14, 41).
Thus, we wanted to compare the appearance of c-Fos protein
after inductions with both NGF or sodium butyrate. In fig. 2A
an analysis using high resolution acrylamide protein gel is shown.
After administration of sodium butyrate, a broad immunoreactive
band appears at an apparent molecular weight lower than mature
p62 c-Fos protein (fig. 2A, lane 1), between 55 and 62 kDa.
This is in contrast to the Fos protein obtained after NGF induction
(lane 2). The immunoreactive bands in the 40 kDa area are only
slightly modified by sodium butyrate treatment. These data
suggest that a post-translational modification pattern of Fos has
been altered in sodium butyrate-treated cells. The increase in c-
Fos immunoreactivity was significant at 90 minutes and peaked
at 3 hours after the initiation of the treatment (fig. 2B). The
amount of c-Fos immunoreactivity and the pattern of bands in
the higher molecular weight range remained elevated in sodium
butyrate-treated cells up to 90 hours after the exposure (not
shown, see also fig. 2A, lane 1).
The increase in c-Fos immunoreactivity was concentration-
dependent between 0.1 and 6 mM (data not shown). NGF
administration (100 ng/ml) resulted in the induction after 90
minutes of mature p62 c-Fos protein, without effect on the
immunoreactivity in the 40 kDa protein range (fig. 2A).
Induction of c-fos and c-jun by sodium butyrate is
independent of the calmodulin signal transduction pathway
It has previously been shown that the induction of c-fos gene
expression by NGF is independent of the Ca2+-calmodulin
pathway, while the induction by depolarizing agents could be
blocked by chlorpromazine or by the more specific calmodulin
inhibitor W7 (25, 27). Administration of 10 IuM of W7 for 24
hours or a few minutes before the addition of sodium butyrate
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Figure 2. Analysis of Fos protein upon sodium butyrate induction of PC12 cells.
a) Comparison of Fos protein appearance after sodium butyrate (NaB, lane 1)
and NGF (lane 2) inductions after 1 h treatment. On this high- resolution protein
gel the Fos protein appears as a broad, heterogenous band after sodium butyrate
induction in contrast to the homogeneous Fos protein observed after NGF addition
(lanes 1-2). b) Time-course of Fos protein appearance upon sodium butyrate
addition. Levels of Fos protein are sustained also at late times, in contrast to
NGF induction (lanes 1-5, ref. 22). The arrowhead indicate the Fos protein;
the heterogenicity of Fos protein is less noticeable if high-resolution PAGE are
not used. Lanes 6-9: Induction of c-Fos protein by sodium butyrate is independent
of the calmodulin signal transduction pathway. Sodium butyrate induced protein
after 3 h induction ( NaB, lane 8). Addition of W7 calmodulin inhibitor had no
effect on Fos protein production (W7+NaB, lane 9).
did not alter the pattern of accumulation of the c-fos and c-jun
mRNAs by sodium butyrate alone (results not shown).
Pretreatment with W7 also had no effect on the pattern and
intensity of the c-Fos immunoreactive bands when compared to
those obtained with sodium butyrate alone (fig. 2B, lanes 7-9).
Binding to an AP-1 recognition site
It has already been shown that binding to a TRE (TPA-responsive
element), the AP-1 recognition site, is enhanced by TPA-
treatment of fibroblasts and by NGF-treatment of PC12 cells (24).
The increase is due to the rapid modification of both Fos and
Jun oncoproteins induced by the activation of the relative signal
transduction pathways. Because the Fos protein undergoes
unusual modifications upon sodium butyrate induction of PC12
cells (fig. 2), we examined its ability to participate in a TRE-
specific nucleoprotein complex formation. Cellular extracts were
prepared from PC12 cells treated at different times (1 hr to 24
hrs) with sodium butyrate. The results, shown in figure 3, indicate
that the Fos protein forms a specific nucleoprotein complex with
the TRE oligodeoxynucleotide probe (lanes I to 5). No complex
is formed when a mutated TRE probe (8) was used in the same
gel retardation assay (not shown). There are two noteworthy
features in this experiment. First, a significant increase in binding
is detected with the extract from the 6 hrs sodium butyrate-
induction time-point. This is in contrast with TPA or NGF
induction where increase in binding is detectable after 1 h
treatment. This result partly correlates with the delayed induction
of c-jun reported in fig. 1. It has to be noted that the decrease
in Fos protein after 9 hrs induction (see fig. 2) is likely to explain
the absence of further increase in DNA-binding in extracts from
cells induced after 6 hrs. In fact, the quantity of Fos protein peaks
at 3-6 hrs (fig. 2) which correlates with increased binding. Fos
protein might dimerize [with other available Jun proteins and bind
to the TRE (such as JunB and JunD, see fig. 1)]. Second, there
is a detectable increase in the mobility of the nucleoprotein
complex, which might correlate with the decreased size of the
Fos protein (see fig. 2A) or to preferential association of modified
Fos with proteins of the Jun family. We confirmed with specific
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Figure 3. Binding to an AP-l site. a) Nuclear extracts from sodium butyrate-
induced PC12 cells were prepared at several time points (1-24 h); gel-retrdation
binding analysis was performed using an oligoprobe containing the consensus
TGACTCA Jun/AP-I binding site of the human metallothionein II gene (8).
Induction of binding is detectable only at 6 h (lane 4) in contrast to NGF induced
extracts in which induction is observed after 1 h induction (24). b) Binding
inhibition using specific anti-Jun and anti-Fos antibodies was performed as
described (8). Both Fos and Jun oncoproteins participate in the complex binding
to the TRE using the PC12 nuclear extract from 6h-induced cells (compare lane
1 with lanes 2-3).
anti-Fos and anti-Jun antibodies that the DNA-binding complex
required both Fos and Jun oncoproteins (fig. 3B). Non-specific
antibodies were used in control experiments (not shown). These
results imply that both Fos and Jun protein domains required for
dimerization and DNA-binding were functional after sodium
butyrate administration.
Lack of fos autoregulation upon sodium butyrate induction
The Fos oncoprotein trans-regulate the activity of the c-fos
promoter by repressing the serum-inducibility (31). This
mechanism, first studied in fibroblasts, is present also in PC12
cells upon NGF induction. In fig. 4, we show transfection
experiments in which a c-fos-CAT reporter gene has been
introduced in PC12 cells and the NGF inducibility of the promoter
studied (29). The induction by NGF is about 8-fold and has
previously been shown to require the SRE (serum responsive
element) of the c-fos promoter (29; compare lanes 1 and 2). Co-
transfection of a c-fos expression vector strongly inhibits the NGF
induction (lane 3). This result is reminiscent of the autoregulation
exerted by the Fos protein upon serum stimulation (31). A control
expression vector which encodes a Fos protein mutated in the
carboxy terminus has no inhibitory effect (lane 4). Because the
different appearance of the Fos protein upon sodium butyrate
induction and the sustained RNA levels observed after treatment
of cultured PC 12 cells, we wanted to test whether the modified
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Figure 4. Lack of c-fos promoter down-regulation in PC12 cells treated with
sodium butyrate. Lane 1-4: The c-fos-CAT plasmid (containing c-fos promoter
sequences from -404 to +42) transfected in PC12 cells is inducible by NGF
(4h, ref. 29). Co-transfection with the c-fos expression vector BK28 (8) shows
strong inhibition of NGF induction (compare lanes 2-3). Co-transfection with
the BK28/? mutant (lacking the carboxy-terminus of the c-fos coding sequence,
see ref. 31) shows lack of down-regulation (lane 4). Lanes 5-8: Induction with
sodium butyrate (8h) is obtained after transfection of the c-fos-CAT plasmid (lanes
5-6); no down-regulation is observed after co-transfection of the c-fos expression
vectors (lanes 7-8).
Fos protein would repress c-fos induced transcription. In cells
transfected with the c-fos-CAT plasmid we obtained induction
of the promoter after treatment with sodium butyrate (lanes 5-6).
Co-transfection with a c-fos expression vector failed in showing
autoregulation by Fos protein since no repression of the induced
level was detectable (lane 7). This result suggest that one reason
of the sustained c-fos transcription in PC12 cells induced with
sodium butyrated may be the lack of the trans-repressor function
of the Fos protein.
DISCUSSION
Sodium butyrate has been shown to be a potent differentiation
inducing agent in a wide variety of cells. In Friend
erythroleukemia cells (42), Manin-Darby canine kidney cells (43),
rat pancreatic islet tumor cells (44) or NCB-20 cells (a hybrid
resulting from fusion of neuroblastoma N18TG2 and Chinese
hamster 18-day embryonic brain cell) (45), sodium butyrate has
profound effects on cell division, morphology and expression of
specific target genes. It has been hypothesized that sodium
butyrate modifies chromatin structure by increasing the degree
of histone acetylation (46) since it has been shown to inhibit
histone deacetylases (47). The exact mechanism by which sodium
butyrate stops PC 12 pheochromocytoma cell division and gives
rise to the endocrine-chromaffin phenotype is not yet known
(4, 5).
Differentiation of PC12 pheochromocytoma cells along the
endocrine pathway resulted in a stable high level of c-fos and
c-jun mRNAs which correlates with the constitutively high levels
of both proto-oncogene products observed in cultures of
chromaffin cells from bovine adrenal medulla or in adrenal
medulla from adult rat (J.R.N. unpublished results). Whether
a stable high level of c-jun gene expression is a consequence of
high levels of c-Fos protein or is an independent effect of sodium
butyrate remains to be established. A prolonged activation of c-
jun gene (at least six hours) with levels of c-Fos protein only
transiently increased, has been reported in human fibroblasts after
the addition of tumor necrosis factor-a (48).
Differentiation of PC12 pheochromocytoma cells along the
neuronal pathway has been associated with a transient induction
of c-fos, c-jun and jun B genes (19-24, 28), and to a minor
extent of the c-myc gene (20-23). Stable high expression of some
non-nuclear proto-oncogenes such as c-src (49) and c-Ha-ras (24,
50-52) induces the neuronal phenotype may be through the
activation of similar molecular mechanisms triggered by NGF
(24).
The late induction of c-jun differs from the effects observed
with NGF treatment of PC12 cells (24, 41). On the other hand,
jun D, which shows a very weak response to serum stimulation
(17), is slightly induced after sodium butyrate differentiation (see
fig. lA). The fact that sodium butyrate affects the expression
ofjun related genes in such a different way than NGF may point
to distinctive regulation and functions within this group of early
response genes. This is supported by the previous observation
that c-jun and jun-B induction can be dissociated in PC12
pheochromocytoma cells after membrane depolarization (28).
A novel conclusion from our studies is that the induction of
high levels of c-fos mRNA and c-jun mRNA by sodium butyrate
correlates with a distinctive post-translational processing of the
c-Fos protein, which is still capable of efficient binding to the
TRE sequence. Similar characteristics in the maturation of c-Fos
protein have been described in PC12 cells after c-fos induction
by depolarizing stimuli (25, 27). Results from Curran and Morgan
(27) indicate that a group of c-Fos immunoreactive bands in the
range 50 to 62 kDa followed an accumulation of c-fos mRNA
shortly after the depolarization. However, these effects were more
transient than those observed after sodium butyrate treatment.
Furthermore, differently from the results obtained with sodium
butyrate, the increase in both c-fos mRNA and c-Fos
immunoreactivity after depolarization is sensitive to calmodulin
inhibitor W7 (27). These differences suggest that a distinct
mechanism contributes to butyrate- induced changes in proto-
oncogene expression with respect to those induced by NGF or
depolarizing agents.
Interestingly, when gel shift analysis was applied to study the
ability of the immature forms of c-Fos protein to form a
nucleoprotein complex with Jun/AP-1, no obvious change in
binding capacity to a TRE was observed. However, butyrate
induced-binding showed a lower molecular form of the complex
formed as compared to HeLa cell nuclear extracts (data not
shown) or to untreated PC12 cells; this is likely to be explained
by the Western blot results which showed an unusually modified
Fos protein (fig. 2A). Thus, apparently, the Fos protein obtained
after sodium butyrate induction is able to participate in the
formation of a stable complex and consequently its ability to
dimerize with Jun/AP-1 appears unaffected.
The Fos product is known to have pleiotropic regulatory
functions (8-13, 31). Particularly, it has been shown that p55fos
is involved in the negative regulation of the c-fos promoter after
serum induction (31). Because of the sustained elevation offos
mRNA after sodium butyrate induction and the unusual
modifications which the Fos protein undergoes (fig. 2A), we
reasoned that the lack of down-regulation of thefos mRNA level
might be due to loss of the autoregulatory function by the Fos
protein. From the transfection experiment performed (fig. 4) it
appears that p55fos modifications induced by NGF or sodium
butyrate treatments have distinct effect on the autoregulatory
activity. The Fos product induced by sodium butyrate is unable
to trans-regulate the c-fos promoter, strongly suggesting that this
is one reason for the sustained fos mRNA level. It is tempting
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to speculate that the modifications which the Fos protein
undergoes are directly affecting its trans-regulatory function.
Since it has been shown that the carboxy-terminus of the Fos
protein is involved in the autoregulation of the gene transcription
(ref. 31 and fig. 4), it is conceivable that sodium butyrate might
affect that domain of the Fos protein. In the carboxy terminus
of Fos are located clusters of serine residues that are known sites
of phosphorylation (39). Thus, it could be that sodium butyrate
treatment might affect Fos protein phosphorylation. This
hypothesis is currently under investigation. These results also
indicate that sodium butyrate-induced changes in c-fos gene
expression are likely to be independent of conformational
modifications in chromatin structure. Alternatively, sodium
butyrate could activate another factor which inhibits Fos
autoregulatory function.
It has also been suggested thatfos mRNA is unstable, because
of the presence of specific AUUUA sequences in the
3'-untranslated region of the messenger (53). It would be
interesting to analyze the mechanism offos mRNA stability in
sodium butyrate induced PC12 cells, which clearly differs from
NGF treated cells (22, 24). It could be argued that the Fos protein
might participate in the molecular processes involved in the fos
mRNA instability. The unusual protein modifications which
occurs during sodium butyrate induction would then prevent this
putative action of the Fos product.
The PC12 cell line provides an excellent model for the study
of neuroendocrine differentiation. Because of the putative role
played by proto-oncogenes in cellular proliferation and
physiology, it is likely that their study will help us understand
the molecular mechanisms involved. The use of PC12 cells
induced to differentiate by sodium butyrate also appears to
constitute an useful tool for the study of fos function. It is
conceivable, indeed, that the accurate analysis of Fos protein
modifications upon sodium butyrate treatment will contribute to
the characterization of the Fos protein domains responsible of
the gene autoregulation function.
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